# Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial

Study · id `cardio:ct-nct05309460` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05309460](<https://clinicaltrials.gov/study/NCT05309460>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05309460

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.

## Technical summary

Registry record NCT05309460. Randomized; no masking; primary purpose treatment. Start 2022-06-20 (actual); primary completion 2024-05-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 600 participants (planned count; ClinicalTrials.gov record NCT05309460, source copy `cardio:ctgov-nct05309460-2024-04-12`, retrieved 2026-10-26)
- Started: 2022-06-20 (actual) (ClinicalTrials.gov record NCT05309460, source copy `cardio:ctgov-nct05309460-2024-04-12`, retrieved 2026-10-26)
- Primary completion: 2024-05-01 (anticipated) (ClinicalTrials.gov record NCT05309460, source copy `cardio:ctgov-nct05309460-2024-04-12`, retrieved 2026-10-26)
- Completion: 2024-12-01 (anticipated) (ClinicalTrials.gov record NCT05309460, source copy `cardio:ctgov-nct05309460-2024-04-12`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05309460, source copy `cardio:ctgov-nct05309460-2024-04-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05309460-2024-04-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial
- Condition: Postpartum Preeclampsia
- Condition: Hypertension in Pregnancy
- Intervention (Drug): Labetalol Oral Tablet
- Intervention (Drug): NIFEdipine ER
- Lead sponsor: Nebraska Methodist Health System
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: 74c1a80eecfeef08d69064c5b73f0ef64fef210587a3e4e044a47a9f448074f8
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
